Yaser Atlasi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5913020/publications.pdf Version: 2024-02-01



ΥΛΩΕΡ ΔΤΙΛΩΙ

#	Article	IF	CITATIONS
1	<i>CCAT2</i> , a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Research, 2013, 23, 1446-1461.	2.4	526
2	The interplay of epigenetic marks during stem cell differentiation and development. Nature Reviews Genetics, 2017, 18, 643-658.	7.7	414
3	OCT4 Spliced Variants Are Differentially Expressed in Human Pluripotent and Nonpluripotent Cells. Stem Cells, 2008, 26, 3068-3074.	1.4	252
4	OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. International Journal of Cancer, 2007, 120, 1598-1602.	2.3	241
5	Dynamic Reorganization of Extremely Long-Range Promoter-Promoter Interactions between Two States of Pluripotency. Cell Stem Cell, 2015, 17, 748-757.	5.2	179
6	Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. Molecular Cell, 2016, 61, 520-534.	4.5	142
7	Wnt Signaling Regulates the Lineage Differentiation Potential of Mouse Embryonic Stem Cells through Tcf3 Down-Regulation. PLoS Genetics, 2013, 9, e1003424.	1.5	76
8	OCT4B1, a novel spliced variant of <i>OCT4</i> , is highly expressed in gastric cancer and acts as an antiapoptotic factor. International Journal of Cancer, 2011, 128, 2645-2652.	2.3	68
9	Epigenetic modulation of a hardwired 3D chromatin landscape in two naive states of pluripotency. Nature Cell Biology, 2019, 21, 568-578.	4.6	55
10	Control of embryonic stem cell self-renewal and differentiation via coordinated alternative splicing and translation of YY2. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 12360-12367.	3.3	54
11	Queuine links translational control in eukaryotes to a micronutrient from bacteria. Nucleic Acids Research, 2019, 47, 3711-3727.	6.5	53
12	STARR-seq identifies active, chromatin-masked, and dormant enhancers in pluripotent mouse embryonic stem cells. Genome Biology, 2020, 21, 243.	3.8	48
13	Cancer Stem Cells, Pluripotency, and Cellular Heterogeneity. Current Topics in Developmental Biology, 2014, 107, 373-404.	1.0	40
14	Differential expression of survivin and its splice variants, survivin-ΔEx3 and survivin-2B, in bladder cancer. Cancer Detection and Prevention, 2009, 32, 308-313.	2.1	27
15	Dynamic CpG methylation delineates subregions within super-enhancers selectively decommissioned at the exit from naive pluripotency. Nature Communications, 2020, 11, 1112.	5.8	25
16	The translational landscape of ground state pluripotency. Nature Communications, 2020, 11, 1617.	5.8	18
17	Overexpression of BMI1, a polycomb group repressor protein, in bladder tumors: a preliminary report. Urology Journal, 2008, 5, 99-105.	0.3	16
18	Differential expression of nucleostemin, a stem cell marker, and its variants in different types of brain tumors. Molecular Carcinogenesis, 2010, 49, 818-825.	1.3	14

YASER ATLASI

#	Article	IF	CITATIONS
19	The role of S100a4 (Mts1) in Apc- and Smad4-driven tumour onset and progression. European Journal of Cancer, 2016, 68, 114-124.	1.3	11
20	Cancer Stemness in Apc- vs. Apc/KRAS-Driven Intestinal Tumorigenesis. PLoS ONE, 2013, 8, e73872.	1.1	8
21	A Me6Age for pluripotency. Science, 2015, 347, 614-615.	6.0	6
22	Ectopic activation of WNT signaling in human embryonal carcinoma cells and its effects in short- and long-term in vitro culture. Scientific Reports, 2019, 9, 11928.	1.6	6
23	WNT-Regulated Transcriptional Enhancers and Stem Cell Plasticity. Trends in Cell Biology, 2021, 31, 525-528.	3.6	1
24	Detection of OCT-4 in Bladder Cancer: Role of Cancer Stem Cell. , 2010, , 211-226.		0
25	Brd4-independence in ground state pluripotency. Nature Cell Biology, 2018, 20, 513-515.	4.6	0